BLTE Belite Bio, Inc
USHealthcareAs of 2026-07-08 16:00
Why BLTE matters now
Belite Bio, Inc (BLTE) is a US stock in Healthcare. The latest InvestLog snapshot shows $152.30 with -3.42% on the session and $6.10B in market capitalization; recent performance reads 1-month +4.60% and YTD -8.65%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-26.9M, and EPS of $-0.68. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.0%.
The latest indexable market news headline is "Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $215.00; recent insider activity includes Scholl Hendrik Peter filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.56
P/S
0.00
EV/EBITDA
-57.59
DCF Value
$10.53
FCF Yield
-0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.7%
ROA
-11.6%
ROIC
-13.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-26.9M | $-0.68 |
| Q4 2025 | $0.00 | $-25.3M | $-0.72 |
| FY 2025 | $0.00 | $-77.6M | $-2.31 |
| Q3 2025 | $0.00 | $-21.7M | $-0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$208.00
Target (Median)
$215.00
Target Range
$191.00 - $217.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.24
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.